A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys

Bone

Volumn 40, Issue 1, 2007, Pages 122-131

  Kumar, S ^a   Dare, L ^a   Vasko Moser, J A ^a   James, I E ^a   Blake, S M ^a   Rickard, D J ^a   Hwang, S M ^a   Tomaszek, T ^a   Yamashita, D S ^a   Marquis, R W ^a   Oh, H ^a   Jeong, J U ^a   Veber, D F ^a   Gowen, M ^a   Lark, M W ^a   Stroup, G ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Biomarker; Bone resorption; Cathepsin K; Inhibitor, Relacatib; Monkey

Indexed keywords

BIOLOGICAL MARKER; CATHEPSIN K; CATHEPSIN K INHIBITOR; COLLAGEN TYPE 1; RELACATIB; TELOPEPTIDE;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; BIOLOGICAL MONITORING; BONE TURNOVER; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DISEASE MODEL; DOSE TIME EFFECT RELATION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; EVALUATION; EXPERIMENTAL MODEL; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MONKEY; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; REPEATED DRUG DOSE; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ANIMALS; AZEPINES; BIOLOGICAL MARKERS; BONE RESORPTION; CATHEPSINS; CELLS, CULTURED; COLLAGEN TYPE I; DISEASE MODELS, ANIMAL; HUMANS; MACACA FASCICULARIS; OSTEOCLASTS; PEPTIDES; SULFONES;

EID: 33751504918     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2006.07.015     Document Type: Article

References (53)

1. Atley L.M., Mort J.S., Lalumiere M., and Eyre D.R. Proteolysis of human bone collagen by cathepsin K: characterization of the cleavage sites generating the cross-linked N-telopeptide neoepitope. Bone (N.Y.) 26 (2000) 241-247
2. Black D.M., Greenspan S.L., Ensrud K.E., Palermo L., McGowan J.A., Lang T.F., et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med. 349 (2003) 1207-1215
3. Bossard M.J., Tomaszek T.A., Thompson S.K., Amegadzie B.Y., Hanning C.R., Jones C., et al. Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification. J. Biol. Chem. 271 (1996) 12517-12524
4. Calvo M.S., Eyre D.R., and Gundberg C.M. Molecular basis and clinical application of biological markers of bone turnover. Endocr. Rev. 17 (1996) 333-368
5. Chestnut III C.H., and Rosen C.J. Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture. J. Bone Miner. Res. 16 (2001) 2163-2172
6. Deaton D.N., and Kumar S. Cathepsin K inhibitors: their potential as anti-osteoporosi agents. In: King F.D.G., and Lawton A.W. (Eds). Progress in medicinal chemistry vol. 42 (2004), Elsevier B.V., Amsterdam 245-375
7. Delaisse J.M., Eeckhout Y., and Vaes G. Inhibition of bone resorption in culture by inhibitors of thiol proteinases. Biochem. J. 192 (1980) 365-368
8. Dodds R.A., Connor J.R., Drake F., Feild J., and Gowen M. Cathepsin K mRNA detection is restricted to osteoclasts during fetal mouse development. J. Bone Miner. Res. 13 (1998) 673-682
9. Dodds R.A., James I.E., Rieman D., Ahern R., Hwang S.M., Connor J.R., et al. Human osteoclast cathepsin K is processed intracellularly prior to attachment and bone resorption. J. Bone Miner. Res. 16 (2001) 478-486
10. Drake F.H., Dodds R.A., James I.E., Connor J.R., Debouck C., Richardson S., et al. Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J. Biol. Chem. 271 (1996) 12511-12516
11. Eyre D.R. The specificity of collagen cross-links as markers of bone and connective tissue degradation. Acta Orthop. Scand. 66 Suppl. 266 (1995) 166-170
12. Finkelstein J.S., Hayes A., Hunzelman J.L., Wyland J.J., Lee H., and Neer R.M. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N. Engl. J. Med. 349 (2003) 1216-1226
13. Garnero P., Borel O., Byrjalsen I., Ferreras M., Drake F.H., McQueney M.S., et al. The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J. Biol. Chem. 273 (1998) 32347-32352
14. Garnero P., Ferreras M., Karsdal M.A., Nicamhlaoibh R., Risteli J., Borel O., et al. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J. Bone Miner. Res. 18 (2003) 859-867
15. Garnero P., Sornay-Rendu E., Chapuy M.C., and Delmas P.D. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J. Bone Miner. Res. 11 (1996) 337-349
16. Gelb B.D., Shi G.-P., Chapman H.A., and Desnick R.J. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 273 (1996) 1236-1238
17. Gowen M., Lazner F., Dodds R., Kapadia R., Feild J., Tavaria M., et al. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J. Bone Miner. Res. 14 (1999) 1654-1663
18. Honey K., and Rudensky A.Y. Lysosomal cysteine proteases regulate antigen presentation. Nat. Rev., Immunol. 3 (2003) 472-482
19. Inui T., Ishibashi O., Inaoka T., Origane Y., Kumegawa M., Kokubo T., et al. Cathepsin K antisense oligodeoxynucleotide inhibits osteoclastic bone resorption. J. Biol. Chem. 272 (1997) 8109-8112
20. James I.E., Lark M.W., Zembryki D., Lee-Rykaczewski E.V., Hwang S.M., Tomaszek T.A., et al. Development and characterization of a human in vitro resorption assay: demonstration of utility using novel antiresorptive agents. J. Bone Miner. Res. 14 (1999) 1562-1569
21. James I.E., Marquis R.W., Blake S.M., Hwang S.M., Gress C.J., Ru Y., et al. Potent and selective cathepsin L inhibitors do not inhibit human osteoclast resorption in vitro. J. Biol. Chem. 276 (2001) 11507-11511
22. Jerome C., Missbach M., and Gamse R. AAE581, a novel cathepsin K inhibitor, protects against ovariectomy-induced bone loss in non-human primates, in part by stimulation of periosteal bone formation. J. Bone Miner. Res. 20 Suppl. 1 (2005) S46
23. Kiviranta R., Morko J., Uusitalo H., Aro H.T., Vuorio E., and Rantakokko J. Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K. J. Bone Miner. Res. 16 (2001) 1444-1452
24. Kumar S., Rehm S., Boyce R., Birmingham J., Stroup G., Jerome C., et al. Treatment of young male monkeys for 12 months with a highly potent inhibitor of cathepsin K inhibits bone resorption, and increases bone mineral density and strength. J. Bone Miner. Res. 20 Suppl. 1 (2005) S80
25. Lark M.W., Stroup G.B., James I.E., Dodds R.A., Hwang S.M., Blake S.M., et al. A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat. Bone 30 (2002) 746-753
26. Marquis R.W. Inhibition of the cysteine protease cathepsin K (EC 3.4.22.38). Annu. Rep. Med. Chem. 39 (2004) 79-98
27. Marquis R.W., Ru Y., LoCastro S.M., Zeng J., Yamashita D.S., Oh H.-J., et al. Azepanone-based inhibitors of human and rat cathepsin K. J. Med. Chem. 44 (2001) 1380-1395
28. Marquis R.W., Ru Y., Zeng J., Trout R.E.L., LoCastro S.M., Gribble A.D., et al. Cyclic ketone inhibitors of the cysteine protease cathepsin K. J. Med. Chem. 44 (2001) 725-736
29. Marquis R.W., Ward K.W., Roethke T., Smith B.R., Ru Y., Yamashita D.S., et al. An azepanone-based inhibitor of human cathepsin K with improved oral bioavailability in the rat and the monkey. Mol. Pharm. 1 (2004) 97-100
30. Marquis R.W., Yamashita D.S., Ru Y., LoCastro S.M., Oh H.J., Erhard K.F., et al. Conformationally constrained 1,3-diamino ketones: a series of potent inhibitors of the cysteine protease cathepsin K. J. Med. Chem. 41 (1998) 3563-3567
31. McQueney M.S., Feild J., Hanning C.R., Brun K., Ramachandran K., Connor J., et al. Cynomolgus monkey (Macaca fascicularis) cathepsin K: cloning, expression, purification, and activation. Protein Expr. Purif. 14 (1998) 387-394
32. Nakagawa T., Roth W., Wong P., Nelson A., Farr A., Deussing J., et al. Cathepsin L: critical role in Ii degradation and CD4 T cell selection in the thymus. Science 280 (1998) 450-453
33. Nakagawa T.Y., Brissette W.H., Lira P.D., Griffiths R.J., Petrushova N., Stock J., et al. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity 10 (1999) 207-217
34. Ochi Y., Kawada N., Yamada H., Mori H., Kayasuga R., Tanaka M., et al. Pretreatment with cathepsin K inhibitor but not alendronate demonstrated further increases in bone mineral density in ovariectomized rats followed by add-on treatment with parathyroid hormone. J. Bone Miner. Res. 19 (2004) S358
35. Pennypacker B., and Kimmel D. Bone formation phenotype in cathepsin K null mice. J. Bone Miner. Res. 19 (2004) S22
36. Potts W., Bowyer J., Jones H., Tucker D., Freemont A.J., Millest A., et al. Cathepsin L-deficient mice exhibit abnormal skin and bone development and show increased resistance to osteoporosis following ovariectomy. Int. J. Exp. Pathol. 85 (2004) 85-96
37. Reszka A.A., and Rodan G.A. Nitrogen-containing bisphosphonate mechanism of action. Mini. Rev. Med. Chem. 4 (2004) 711-719
38. Rodan G., Reszka A., Golub E., and Rizzoli R. Bone safety of long-term bisphosphonate treatment. Curr. Med. Res. Opin. 20 (2004) 1291-1300
39. Rosen C.J., Hochberg M.C., Bonnick S.L., McClung M., Miller P., Broy S., et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J. Bone Miner. Res. 20 (2005) 141-151
40. Roth W., Deussing J., Botchkarev V.A., Pauly-Evers M., Saftig P., Hafner A., et al. Cathepsin L deficiency as molecular defect of furless: hyperproliferation of keratinocytes and perturbation of hair follicle cycling. FASEB J. 14 (2000) 2075-2086
41. Saftig P., Hunziker E., Everts V., Jones S., Boyde A., Wehmeyer O., et al. Functions of cathepsin K in bone resorption: lessons from cathepsin K deficient mice. Adv. Exp. Med. Biol. 477 (2000) 293-303
42. Saftig P., Hunziker E., Wehmeyer O., Jones S., Boyde A., Rommerskirch W., et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 13453-13458
43. Santamaria I., Velasco G., Cazorla M., Fueyo A., Campo E., and Lopez-Otin C. Cathepsin L2, a novel human cysteine proteinase produced by breast and colorectal carcinomas. Cancer Res. 58 (1998) 1624-1630
44. Stroup G., Jerome C., Yamashita D.S., and Kumar S. SB-462795, a cathepsin inhibitor, prevents the loss of bone mass at several sites in ovariectomized cynomolgus monkeys. J. Bone Miner. Res. 20 Suppl. 1 (2005) S142
45. Stroup G.B., Hoffman S.J., Vasko-Moser J.A., Lechowska B.A., Jenkins E.L., Dare L.C., et al. Changes in bone turnover following gonadotropin-releasing hormone (GnRH) agonist administration and estrogen treatment in cynomolgus monkeys: a short-term model for evaluation of antiresorptive therapy. Bone 28 (2001) 532-537
46. Stroup G.B., Lark M.W., Veber D.F., Bhattacharyya A., Blake S., Dare L.C., et al. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate. J. Bone Miner. Res. 16 (2001) 1739-1746
47. Stroup G.S., Jerome C., Yamashita D.S., and Kumar S. Histomorphometric and biochemical evidence for a cortical bone-forming effect of a cathepsin K inhibitor in ovariectomized cynomolgus monkeys. J. Bone Miner. Res. 20 Suppl. 1 (2005) S80
48. Wehren L.E., Hosking D., and Hochberg M.C. Putting evidence-based medicine into clinical practice: comparing anti-resorptive agents for the treatment of osteoporosis. Curr. Med. Res. Opin. 20 (2004) 525-531
49. Xia L., Kilb J., Wex H., Li Z., Lipyansky A., Breuil V., et al. Localization of rat cathepsin K in osteoclasts and resorption pits. Inhibition of bone resorption and cathepsin K-activity by peptidyl vinyl sulfones. Biol. Chem. 380 (1999) 679-687
50. Yamashita D.S., Marquis R.W., Xie R., Nidamarthy S.D., Oh H.J., Jeong J.U., et al. Structure activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one cathepsin K inhibitors. J. Med. Chem. 49 (2006) 1597-1612
51. Yamashita D.S., Smith W.W., Zhao B., Janson C.A., Tomaszek T.A., Bossard M.J., et al. Structure and design of potent and selective cathepsin K inhibitors. J. Am. Chem. Soc. 119 (1997) 11351-11352
52. Yasuda Y., Kaleta J., and Bromme D. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. Adv. Drug Delivery Rev. 57 (2005) 973-993
53. Zhang T., Maekawa Y., Hanba J., Dainichi T., Nashed B.F., Hisaeda H., et al. Lysosomal cathepsin B plays an important role in antigen processing, while cathepsin D is involved in degradation of the invariant chain inovalbumin-immunized mice. Immunology 100 (2000) 13-20